Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 429-435

  Shi, Jianxin ^a   Zhu, Ji ^b   Zhao, Heng ^a   Zhong, Chenxi ^a   Xu, Zhiyun ^b   Yao, Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer metabolism; ERK; ESCC; Mevalonate pathway

Indexed keywords

CYCLIN D1; CYCLINE; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84872800656     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0567-0     Document Type: Article

References (24)

1. R Siegel 2012 Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 220 241 22700443 10.3322/caac.21149
2. J Koshiol, et al. 2010 No role for human papillomavirus in esophageal squamous cell carcinoma in China Int J Cancer 127 93 100 19918949 10.1002/ijc.25023 1:CAS:528:DC%2BC3cXlsVOrsbk%3D
3. X Zhao, et al. 2011 Loss of heterozygosity at 6p21 and HLA class I expression in esophageal squamous cell carcinomas in China Asian Pac J Cancer Prev 12 2741 2745 22320985
4. YH Chen, et al. 2012 Comparative study of esophageal stent and feeding gastrostomy/jejunostomy for tracheoesophageal fistula caused by esophageal squamous cell carcinoma PLoS One 7 e42766 22912737 10.1371/journal.pone.0042766 1:CAS:528:DC%2BC38Xht1amsr3M
5. JL Goldstein MS Brown 1990 Regulation of the mevalonate pathway Nature 343 425 430 1967820 10.1038/343425a0 1:CAS:528:DyaK3cXhtlCmtbw%3D
6. A Endo, et al. 1992 The discovery and development of HMG-CoA reductase inhibitors J Lipid Res 33 1569 1582 1464741 1:CAS:528:DyaK3sXhsFOhuw%3D%3D
7. MH Davidson, et al. 2001 Safety profiles for the HMG CoA reductase inhibitors: treatment and trust Drugs 61 197 206 11270938 10.2165/00003495- 200161020-00005 1:CAS:528:DC%2BD3MXit1ent78%3D
8. O Larsson, et al. 1996 HMG-CoA reductase inhibitors: role in normal and malignant cells Crit Rev Oncol Hematol 22 197 212 8793275 10.1016/1040-8428(96) 00193-X 1:STN:280:DyaK28zosFCitQ%3D%3D
9. H Mo CE Elson 2004 Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention Exp Biol Med 229 567 585 1:CAS:528:DC%2BD2cXlslWqsL8%3D
10. RE Duncan A El-Sohemy MC Archer 2004 Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity J Biol Chem 279 33079 33084 15155733 10.1074/jbc.M400732200 1:CAS:528:DC%2BD2cXmtFOis7k%3D
11. JA Cauley, et al. 2006 Statin use and breast cancer: prospective results from the Women's Health Initiative J Natl Cancer Inst 98 700 707 16705124 10.1093/jnci/djj188 1:CAS:528:DC%2BD28XkvVSrs7w%3D
12. AS Kumar, et al. 2008 Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users Cancer Epidemiol Biomarkers Prev 17 1028 1033 18463402 10.1158/1055-9965.EPI-07-0726 1:CAS:528: DC%2BD1cXmtVClsL4%3D
13. R Kochhar V Khurana H Bejjanki G Caldito C Fort 2005 Statins reduce breast cancer risk: a case control study in US female veterans J Clin Oncol 23 514
14. ML Kwan LA Habel ED Flick CP Quesenberry B Caan 2008 Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors Breast Cancer Res Treat 109 573 579 17674197 10.1007/s10549-007-9683-8 1:CAS:528:DC%2BD1cXlvVCgt74%3D
15. KR Solomon MR Freeman 2008 Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19 113 121 18356074 10.1016/j.tem.2007.12.004 1:CAS:528:DC%2BD1cXlslWrsro%3D
16. I Karp H Behlouli J Lelorier L Pilote 2008 Statins and cancer risk Am J Med 121 302 309 18374689 10.1016/j.amjmed.2007.12.011 1:CAS:528: DC%2BD1cXktVCksr0%3D
17. SM Lipkin, et al. 2010 Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer Cancer Prev Res 3 597 603 10.1158/1940-6207.CAPR-10-0007 1:CAS:528:DC%2BC3cXhtlGjsL%2FK
18. ED Kantor, et al. 2012 Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus Cancer Epidemiol Biomarkers Prev 21 456 461 22241250 10.1158/1055-9965.EPI-11-1014 1:CAS:528: DC%2BC38Xjs1SitrY%3D
19. A Mohammed, et al. 2012 Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48(Cre/+) LSL-Kras(G12D/+) mice Int J Cancer 131 1951 1962 22287227 10.1002/ijc.27456 1:CAS:528:DC%2BC38Xjs1ygt7c%3D
20. W James, et al. 2010 Dysregulation of the mevalonate pathway promotes transformation Proc Natl Acad Sci U S A 107 15051 15056 10.1073/pnas.0910258107
21. V Pallottini, et al. 2008 Regulation of HMG-CoA reductase expression by hypoxia J Cell Biochem 104 701 709 18459144 10.1002/jcb.21757 1:CAS:528:DC%2BD1cXntlWhtLY%3D
22. MF Demierre PD Higgins SB Gruber, et al. 2005 Statins and cancer prevention Nat Rev Cancer 5 930 942 16341084 10.1038/nrc1751 1:CAS:528:DC%2BD2MXht1ykurbL
23. MR Graaf DJ Richel CJ van Noorden, et al. 2004 Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer Cancer Treat Rev 30 609 641 15531395 10.1016/j.ctrv.2004.06.010 1:CAS:528:DC%2BD2cXpsVOltb0%3D
24. L Vincent W Chen L Hong, et al. 2001 Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect FEBS Lett 495 159 166 11334884 10.1016/S0014-5793(01) 02337-7 1:CAS:528:DC%2BD3MXjtFGht7w%3D